Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis.

Subcutaneous interferon beta-1a (Rebif) therapy has been recognized as a significant advance in the treatment of relapsing-remitting multiple sclerosis (MS). The drug is supplied as a solution in a ready-to-use prefilled syringe. Given the chronic nature of the disease, a convenient and simple drug delivery for self-administration improves patient management. Home-based therapy requires comprehensive knowledge of multiple sclerosis and a training and support program to ensure maximum convenience and independence for the patient. These result in high compliance with therapy and optimum response to treatment.